Page 134 - Haematologica - Vol. 105 n. 6 - June 2020

F. Drieux et al.
Fabiani, A.Aline-Fardin, P. Coppo, Hôpital Saint-Antoine, Paris, France; F. Charlotte, J. Gabarre, Hôpital Pitié- Salpétrière, Paris, France; T. Molina, J. Bruneau, D. Canioni, E. Macintyre, V. Asnafi, D. Sibon, R. Delarue, JP Jaïs, Hôpital Necker, Paris, France; M. Parrens, J.P.Merlio, K. Bouabdallah, Hôpital Haut Lévêque, Bordeaux, France; S. Maugendre- Caulet, P. Tas,F. Llamas-Gutierrez T. Lamy, CHU Pontchaillou, Rennes, France; J.M. Picquenot, E.L Veresezan, F. Drieux, P. Ruminy, F. Jardin, C.Bastard, Centre H Becquerel, Rouen, France; M. Peoch', J. Cornillon, CHU, Saint Etienne, France; L. Lamant, C. Laurent, L. Ysebaert, Hôpital Purpan,
Toulouse, France; J.Bosq, P. Dartigues, V. Ribrag, P. Dessen, G Meurice, Institut G Roussy, Villejuif, France; M. Patey, A. Delmer, Hôpital R. Debré, Reims, France; J.F. Emile, K. Jondeau, Hôpital Ambroise Paré, Boulogne, France; M.C. Rousselet, M. Hunault, A. Clavert, CHU, Angers, France ; C. Legendre, S. Castaigne, A.L.Taksin, CH Versailles, Le Chesnay, France; J. Vadrot, B. Joly, A. Devidas, CH Sud Francilien, Corbeil, France; G. Damaj, CHU Caen, France; F Radvanyi, E. Chapeaublanc, Institut Curie, Paris, France; S. Spicuglia, CIML, Marseille, France; C. Thibault, IGBMC, Illkirsch, France; V. Fataccioli, project coordinator, Hôpital Henri Mondor, Créteil, France.
References
1. Swerdlow S., Campo E., Harris N.L et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). Revised 4th Edition. Vol. 2. 2017.
2. Herrera AF, Crosby-Thompson A, Friedberg JW, et al. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network: Second-Opinion Pathology Review of TCL. Cancer. 2014;120(13):1993-1999.
3. Hsi ED, Said J, Macon WR, Rodig SJ, et al. Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas: A North American PTCL Study Group Project. Am J Surg Pathol. 2014;38(6):768-775.
4. Laurent C, Baron M, Amara N, et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol. 2017;35(18):2008-2017.
5. Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T- cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466-1469.
6. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95- 96.
7. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioim- munoblastic T-cell lymphoma. Blood. 2012;119(8):1901-1903.
8. Manso R, Sánchez-Beato M, Monsalvo S, et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lym- phoma and is associated with a characteris- tic molecular signature. Blood. 2014;123 (18):2893-2894.
9. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regu- lators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46 (2):166-170.
10. Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.
11. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lym- phoma is a genetically heterogeneous dis- ease with widely disparate clinical out- comes. Blood. 2014;124(9):1473-1480.
12. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagno- sis in peripheral T-cell lymphoma and prog- nostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036.
13. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T- cell lymphoma. Blood. 2014;123(19):2915- 2923.
14. Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecu- lar and clinical features. Blood. 2014;123(19):3007-3015.
15. Zhang W, Wang Z, Luo Y, Zhong D, Luo Y, Zhou D. GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. Oncotarget. 2016;7(40):65284- 65294.
16. Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664-1676.
17. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805- 812.
18. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblas- tic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11): 4952-4963.
19. Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lym- phomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148-151.
20. Alirkilicarslan AL, Dupuy A, Pujals A, et al. Expression of TFH markers and detection of RHOA p. G17V and IDH2 p. R172K/S
mutations in cutaneous localizations of angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2017;41(12):1581-1592.
21. Dupuy A, Lemonnier F, Fataccioli V, et al. Multiple ways to detect IDH2 mutations in angioimmunoblastic T cell lymphoma: from immunohistochemistry to Next Generation Sequencing. J Mol Diagn. 2018;20(5):677-685.
22. Hsi ED, Horwitz SM, Carson KR, et al. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk. 2017; 17(4):193-200.
23. Mareschal S, Ruminy P, Bagacean C, et al. Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. J Mol Diagn. 2015;17(3):273-283.
24. Bobée V, Ruminy P, Marchand V, et al. Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse TranscriptaseMultiplex Ligation- Dependant Probe Amplification Classifier: a CALYM Study. J Mol Diagn. 2017;19(6): 892-904.
25. Nagata Y, Kontani K, Enami T, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127(5): 596-604.
26. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplas- tic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554-557.
27. Maura F, Agnelli L, Leongamornlert D, et al. Integration of transcriptional and mutation- al data simplifies the stratification of peripheral T cell lymphoma. Am J Hematol. 2019;94(6):628-634.
28. Matutes E. Adult T-cell leukaemia/lym- phoma. J Clin Pathol. 2006;60(12):1373- 1377.
29. Licata MJ, Janakiram M, Tan S, et al. Diagnostic challenges of adult T-cell leukemia/lymphoma in North America – a clinical, histological, and immunopheno- typic correlation with a workflow propos- al. Leuk Lymphoma. 2018;59(5):1188-1194.
30. Gaulard P, de Leval L. The microenviron- ment in T-cell lymphomas: Emerging themes. Semin Cancer Biol. 2014;24:49-60.
1592
haematologica | 2020; 105(6)